skip to main content

Gabapentin renal dosing — GPhC CRA MCQ

Instant feedback + full explanation. One question, done properly.

HardCNS TherapeuticsGabapentin renal dosingGPhC CRA

A patient with eGFR 24 mL/min/1.73 m² takes gabapentin 300 mg three times daily and modified-release morphine. They are markedly drowsy at the counter. What is the safest immediate response?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: DWithhold sedating doses and arrange urgent toxicity and renal-dose review

Withhold sedating doses and arrange urgent toxicity and renal-dose review: Gabapentin is renally eliminated and morphine has active renally cleared metabolites; marked drowsiness may precede respiratory depression and needs assessment before either regimen is merely adjusted. Reduce gabapentin to twice daily and continue morphine pending review: A partial empirical reduction is inadequate when clinically important combined toxicity is already suspected. Continue gabapentin and omit only the next modified-release morphine dose: Both treatments may be contributing in severe renal impairment, so selective self-management without assessment is unsafe. Replace morphine with the same milligram dose of codeine: Codeine also has problematic renally cleared active metabolites and opioid conversion is not milligram-for-milligram. Continue both regimens and recheck eGFR at routine review: The current marked drowsiness is an urgent toxicity signal, not a finding for deferred routine monitoring.

Reference: BNF: gabapentin: https://bnf.nice.org.uk/drugs/gabapentin/; BNF: morphine: https://bnf.nice.org.uk/drugs/morphine/